Related content

Pharmacogenomic considerations of xenograft mouse models of acute leukemia

By Guihard Soizic   Peyrouze Pauline   Cheok Meyling H  

Pharmacogenomics, Vol. 13, Iss. 15, 2012-11 ,pp. : 1759-1772

Future Medicine

Access to resources Recommend Favorite

Clinically Relevant Biomarkers in Acute Heart Failure: An Update

By  

Current Pharmaceutical Biotechnology, Vol. 18, Iss. 6, 2017-08 ,pp. : 482-490

Bentham Science Publishers

Access to resources Recommend Favorite

Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia

By Evangelisti Camilla  

Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 8, 2013-08 ,pp. : 921-936

Informa Healthcare

Access to resources Recommend Favorite

Is Age an Independent Risk Factor for Chemically Induced Acute Myelogenous Leukemia in Children?

By Pyatt David W.   Aylward Lesa L.   Hays Sean M.  

Journal of Toxicology and Environmental Health Part B: Critical Reviews, Vol. 10, Iss. 5, 2007-07 ,pp. : 379-400

Taylor & Francis Ltd

Access to resources Recommend Favorite

Targeting FLT3 Kinase in Acute Myelogenous Leukemia: Progress, Perils, and Prospects

By  

Mini Reviews in Medicinal Chemistry, Vol. 4, Iss. 3, 2004-03 ,pp. : 255-271

Bentham Science Publishers

Access to resources Recommend Favorite